MiR-509-3 augments the synthetic lethality of PARPi by regulating HR repair in PDX model of HGSOC

BACKGROUND: PARP inhibitors have been the most promising target drugs with widely proven benefits among ovarian cancer patients. Although platinum-response, HR-related genes, or HRD genomic scar detection are acceptably used in assessment of Olaparib response, there are still evident limitations in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Hematol Oncol
Autors principals: Sun, Chenggong, Cao, Wenyu, Qiu, Chunping, Li, Chengcheng, Dongol, Samina, Zhang, Zhiwei, Dong, Ruifen, Song, Kun, Yang, Xingsheng, Zhang, Qing, Kong, Beihua
Format: Artigo
Idioma:Inglês
Publicat: BioMed Central 2020
Matèries:
Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6995078/
https://ncbi.nlm.nih.gov/pubmed/32005272
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13045-020-0844-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars